Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll EGFR-mutated lung cancer: a paradigm of molecular oncology Zhang Z; Stiegler AL; Boggon TJ; Kobayashi S; Halmos BOncotarget 2010[Nov]; 1 (7): 497-514The development of EGFR tyrosine kinase inhibitors for clinical use in non-small cell lung cancer and the subsequent discovery of activating EGFR mutations have led to an explosion of knowledge in the fields of EGFR biology, targeted therapeutics and lung cancer research. EGFR-mutated adenocarcinoma of the lung has clearly emerged as a unique clinical entity necessitating the routine introduction of molecular diagnostics into our current diagnostic algorithms and leading to the evidence-based preferential usage of EGFR-targeted agents for patients with EGFR-mutant lung cancers. This review will summarize our current understanding of the functional role of activating mutations, key downstream signaling pathways and regulatory mechanisms, pivotal primary and acquired resistance mechanisms, structure-function relationships and ultimately the incorporation of molecular diagnostics and small molecule EGFR tyrosine kinase inhibitors into our current treatment paradigms.|*Molecular Diagnostic Techniques/methods/standards[MESH]|Animals[MESH]|Antineoplastic Agents/therapeutic use[MESH]|Carcinoma/*diagnosis/drug therapy/*genetics[MESH]|ErbB Receptors/antagonists & inhibitors/*genetics/metabolism[MESH]|Humans[MESH]|Lung Neoplasms/diagnosis/drug therapy/*genetics[MESH]|Medical Oncology/methods/standards[MESH]|Models, Biological[MESH]|Molecular Targeted Therapy/*methods[MESH]|Mutant Proteins/genetics/metabolism[MESH]|Protein Kinase Inhibitors/therapeutic use[MESH] |